Epicutis Reports 8-Week Clinical Findings for New Hydrobiome Serum

Epicutis has introduced Hydrobiome Serum, a new professional skincare product positioned for redness, congestion, and barrier disruption. The formulation centers on TCP, a proprietary isoprenyl cysteine compound developed by Signum Biosciences, and is paired with sodium tocopheryl phosphate, a water-soluble vitamin E derivative intended to support barrier function.

According to the company, the launch is supported by findings from an 8-week, double-blind, placebo-controlled clinical study conducted by Princeton Consumer Research. The study enrolled 48 participants and evaluated a formulation containing TCP against comparator and vehicle control groups. Epicutis reported a 77% improvement in overall skin appearance from baseline in the TCP group, compared with 56% in the comparator group, while the vehicle control showed no measurable improvement. The company also stated that no participants in the TCP arm reported visible irritation, dryness, or discomfort during the study period.

The product is being framed around the concept of “skin imbalance,” which the company describes as a state associated with environmental stress, excess sebum, and impaired barrier function rather than skin type alone. Epicutis says Hydrobiome Serum is intended to address those factors without relying on more aggressive exfoliants or retinoid-based approaches.